News
IONS
41.84
-1.44%
-0.61
Weekly Report: what happened at IONS last week (0415-0419)?
Weekly Report · 3d ago
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 6d ago
ClearBridge Multi Cap Growth Strategy Q1 2024 Portfolio Manager Commentary
Seeking Alpha · 04/17 12:00
Weekly Report: what happened at IONS last week (0408-0412)?
Weekly Report · 04/15 09:10
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Ionis Pharmaceuticals, Inc. Has a price-to-sales ratio of 7.7x. The company's revenue has been rising slower than most other companies. The low P/S ratio may be due to the company's lacklustre revenue growth. Almost half of the Biotechs companies in the U.S. Have a higher price to sales ratio than the company.
Simply Wall St · 04/14 12:55
ClearBridge Aggressive Growth Strategy Q1 2024 Portfolio Manager Commentary
ClearBridge Aggressive Growth Strategy Q1 2024 Portfolio Manager Commentary. The positive momentum of 2023 extended into the first quarter. The S&P 500 Index advanced 10.56% for its best start since 2019. Despite the growing chorus for a soft landing, equities still face an uncertain macro backdrop.
Seeking Alpha · 04/12 11:20
Wolfe upgrades Ionis to outperform, cites upcoming catalysts
Seeking Alpha · 04/10 16:03
Ionis Pharmaceuticals Raised to Outperform From Peer Perform by Wolfe Research
Dow Jones · 04/10 08:42
Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform
Benzinga · 04/10 08:32
The Latest Analyst Ratings For Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Analysts have set 12-month price targets for the company of $64.67 and $75.00. The company has a positive revenue growth rate of 113.65% over the past three months. 9 analysts have shared their evaluations of Ionis pharmaceuticals in the last 3 months.
Benzinga · 04/09 15:01
Madrigal announces US launch of NASH/MASH drug Rezdiffra
Healthcare Madrigal announces US launch of NASH/MASH drug Rezdiffra. The drug is now available in the US through a specialty pharmacy network. Other companies working on therapies for NASH and MASH include Eli Lilly and Novo Nordisk. MadrigAL is the first to receive FDA approval for the treatment of the disease.
Seeking Alpha · 04/09 14:03
Ionis Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Dow Jones · 04/09 12:38
Ionis Pharmaceuticals Price Target Raised to $75.00/Share From $72.00 by Oppenheimer
Dow Jones · 04/09 12:38
Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $75
Benzinga · 04/09 12:27
Ionis Pharmaceuticals (IONS) Gets a Buy from Piper Sandler
TipRanks · 04/09 11:06
Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)
TipRanks · 04/09 11:00
IONIS PHARMACEUTICALS INC <IONS.O>: OPPENHEIMER RAISES TARGET PRICE TO $75 FROM $72
Reuters · 04/09 03:26
Ionis experimental drug meets key goal in familial chylomicronemia study
Ionis Pharmaceuticals announced positive results from a late-stage study of its lead investigational drug, olezarsen. The drug met the primary endpoint of significantly reducing triglycerides in patients with familial chylomicronemia syndrome. Olezarsen reduced the incidence of acute pancreatitis events compared to a placebo.
Seeking Alpha · 04/08 14:16
Stifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)
TipRanks · 04/08 11:15
More
Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About IONS
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).